Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lung cancer patients

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Research Partnership

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

The studies will look at the vaccines in combination with chemotherapy

- PMLiVE

AZ adds another Ionis drug in $330m kidney disease deal

The candidate targets a genetically associated form of the condition

AstraZeneca AZ

AZ bags key lung cancer approval for Imfinzi

Becomes the first PD-1/PD-L1 inhibitor approved to treat inoperable stage III NSCLC patients

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

- PMLiVE

Pfizer files third-gen ALK inhibitor for lung cancer

The US FDA is set to make a decision on lorlatinib later this year

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

AZ expects return to growth this year after 2017 decline

Soriot says the pharma company is 'turning a corner'

The ‘Million Hour Challenge’

AstraZeneca employees save two million hours through simplification

AstraZeneca AZ

Clock starts ticking on AZ’s first-line lung cancer filing in US

FDA priority review of oncology treatment Tagrisso begins

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links